Factors of resistance to progestin therapy in endometrial hyperplasia in women

Authors

Keywords:

endometrial hyperplasia, immunohistochemistry, resistance to progesterone, receptors

Abstract

Background. The article discusses endometrial hyperplasia (EH), a condition in which there is excessive proliferation of glandular and stromal components in the endometrium. EH is divided into atypical EH (simple or complex) and atypical EH (endometrioid intraepithelial neoplasia) based on the binary scoring system of WHO (2014). The risk of developing endometrial cancer (EC) in women with EH depends on several factors, including the type of EH, age, obesity, diabetes, and recurrent abnormal uterine bleeding. Currently, long-term cyclic progesterone therapy is an effective treatment for atypical EH, but ineffectiveness has been reported in some cases, and the reasons for this are not well understood. Objective. The purpose of the article is to investigate the possible causes of resistance of endometrial cells in its hyperplasia to progestin therapy and predict the effectiveness of therapy. Methods. The research uses methods of information-search, bibliographic and comparative analysis. Results. Elucidated causes and mechanisms of progesterone resistance in women with EH, such as genetic factors, hormonal factors, and epigenetic factors. The article emphasizes the need for additional research to understand the main mechanisms of resistance to progesterone therapy in EH. Conclusion. Resistance of endometrial hyperplasia to progestin therapy can be caused by various factors, such as hormone imbalance, abnormal expression of hormone receptors, gene mutations, dysfunction of the immune system, and others. Hormone receptors such as ER, PR and Ki-67 may play an important role in predicting endometrial resistance to progestins and in determining treatment approaches. Studies also show that abnormal expression of factors that control apoptosis, such as Caspase-3 and BAX, may be associated with endometrial resistance to progestins. In addition, disruption of E-cadherin expression can affect the development of endometrial hyperplasia and resistance to progestins. Therefore, the resistance of endometrial hyperplasia to progestin therapy is a complex problem, and more research is needed to understand the role of various factors in the development of this problem and to develop more effective treatment approaches.

References

  1. Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press; 2003.
  2. Trimble CL, Kauderer J, Zaino R, Silver-berg S, Lim PC, Burke JJ, Alberts DS, Barakat RR. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer. 2006;106(4):812-819. doi: 10.1002/cncr.21632
  3. Khaskhachikh DA, Potapov VO, Kukina GO. A differentiated approach to the treatment of endometrial hyperplasia without atypia in women of reproductive age. Curr Issues Pediatr Obstet Gynecol. 2019;2(24):149-154. doi: 10.11603/24116-4944.2019.2.10170
  4. Khaskhachikh DA, Potapov VO, Kukina GO, Gaponova OV. The value of progesterone receptor (PR-A and PR-B) expression as predictors of endometrial hyperplasia recurrence after progestin therapy. Curr Issues Pediatr Obstet Gynecol. 2020;2(46):71-75. doi: 10.11603/24116-4944.2020.2.11714
  5. Gromova OL, Potapov VO, Khaskhachikh DA, Finkova OP, Gaponova OV, Kukina GO, Penner KV. Epigenetic profile of endometrial proliferation in the different morphotypes of endometrial hyperplasia. Reprod Endocrinol. 2021;1(57):73-78. doi: 10.18370/2309-4117.2021.73-78
  6. Gao J, Liang X, Li H, et al. A pilot study of treatment of atypical endometrial hyperplasia with megestrol acetate. Gynecol Obstet Invest. 2013;75(3):185–190. doi: 10.1159/000346408
  7. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, re-lapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2012;207(4):266.e1-12. doi: 10.1016/j.ajog.2012.06.047
  8. Matsuo K, Yabuno A, Hom MS, et al. He-terogeneity of risk for pelvic lymph node metastasis in endometrial cancer. J Obstet Gynaecol Res. 2018;44(5):931–941. doi: 10.1111/jog.13595
  9. Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010;28(5):788–792. doi: 10.1200/JCO.2009.23.1577
  10. Fu M, Feng Y, Fang H, Zhang J, Wang X. Relationship between progesterone resistance and endometrial abnormalities. J Med Res Pract. 2018;3(2):31-36. doi: 10.1016/j.jmrp.2017.08.003
  11. Kim J, Cho K, Lee Y, Kim J, Kim Y. En-dometrial hyperplasia: molecular pathogenesis and new therapeutic opportunities. Korean J Med Sci. 2020;35(4):e37. doi: 10.3346/jkms.2020.35.e37
  12. Sakai K, Yoshida T. Mechanisms of progesterone resistance in endometrial hyperplasia and their impact on pathogenesis and treatment. Biomed Pharmacother. 2020;1(3):44-53. doi: 10.1016/j.biopha.2019.109204
  13. Xu L, Hu C, Qiu C, Yang Z, Xu Q. Proge-sterone resistance and endometrial hyperplasia: latest research and treatment prospects. J Med Sci. 2021;41(2):41-47. doi: 10.3779/j.issn.1009-6574.2021.02.01
  14. Zhang Y, Guo H, Cui X, Song X, Wang Y. Molecular mechanisms of progesterone resistance and their clinical significance in endometrial hyperplasia. J Gynecol Obstet. 2022;1(1):15-22. doi: 10.31083/j.jgo.2022.01.003
  15. Carneiro MM, Pereira RM, Costa LM, Le-mos TA, Reis FM. Genetic mutations and endometrial hyperplasia: unlocking the secret. Int J Gynecol Cancer. 2019;29(6):1106-1113. doi: 10.1136/ijgc-2019-000474
  16. Dong Y, Lu J, Zhang Y, Zhang H, Wang L. Genetic mutations and endometrial hyperplasia: a review of the current advances. J Ovarian Res. 2020;13(1):31. doi: 10.1186/s13048-020-00629-4
  17. Guo F, Wang H. Molecular mechanism and targeted therapy of endometrial hyperplasia. J Oncol. 2020;2020:7282609. doi: 10.1155/2020/7282609
  18. Fu M, Feng Y, Fang H, Zhang J, Wang X. Relationship between progesterone resistance and endometrial abnormalities. J Med Res Pract. 2018;3(2):31-36. doi: 10.1016/j.jmrp.2017.08.003
  19. Kim J, Cho K, Lee Y, Kim J, Kim Y. En-dometrial hyperplasia: molecular pathogenesis and new therapeutic opportunities. Korean J Med Sci. 2020;35(4):e37. doi: 10.3346/jkms.2020.35.e37
  20. Sakai K, Yoshida T. Mechanisms of progesterone resistance in endometrial hyperplasia and their impact on pathogenesis and treatment. Biomed Pharmacother. 2020;1(3):44-53. doi: 10.1016/j.biopha.2019.109204
  21. Xu L, Hu C, Qiu C, Yang Z, Xu Q. Proge-sterone resistance and endometrial hyperplasia: latest research and treatment prospects. J Med Sci. 2021;41(2):41-47. doi: 10.3779/j.issn.1009-6574.2021.02.01
  22. Zhang Y, Guo H, Cui X, Song X, Wang Y. Molecular mechanisms of progesterone resistance and their clinical significance in endometrial hyperplasia. J Gynecol Obstet. 2022;1(1):15-22. doi: 10.31083/j.jgo.2022.01.003
  23. Carneiro MM, Pereira RM, Costa LM, Le-mos TA, Reis FM. Genetic mutations and endometrial hyperplasia: unlocking the secret. Int J Gynecol Cancer. 2019;29(6):1106-1113. doi: 10.1136/ijgc-2019-000474
  24. Dong Y, Lu J, Zhang Y, Zhang H, Wang L. Genetic mutations and endometrial hyperplasia: a review of the current advances. J Ovarian Res. 2020;13(1):31. doi: 10.1186/s13048-020-00629-4
  25. Guo F, Wang H. Molecular mechanism and targeted therapy of endometrial hyperplasia. J Oncol. 2020;2020:7282609. doi: 10.1155/2020/7282609
  26. Fu M, Feng Y, Fang H, Zhang J, Wang X. Relationship between progesterone resistance and endometrial abnormalities. J Med Res Pract. 2018;3(2):31-36. doi: 10.1016/j.jmrp.2017.08.003
  27. Kim J, Cho K, Lee Y, Kim J, Kim Y. En-dometrial hyperplasia: molecular pathogenesis and new therapeutic opportunities. Korean J Med Sci. 2020;35(4):e37. doi: 10.3346/jkms.2020.35.e37
  28. Sakai K, Yoshida T. Mechanisms of progesterone resistance in endometrial hyperplasia and their impact on pathogenesis and treatment. Biomed Pharmacother. 2020;1(3):44-53. doi: 10.1016/j.biopha.2019.109204
  29. Xu L, Hu C, Qiu C, Yang Z, Xu Q. Proge-sterone resistance and endometrial hyperplasia: latest research and treatment prospects. J Med Sci. 2021;41(2):41-47. doi: 10.3779/j.issn.1009-6574.2021.02.01
  30. Zhang Y, Guo H, Cui X, Song X, Wang Y. Molecular mechanisms of progesterone resistance and their clinical significance in endometrial hyperplasia. J Gynecol Obstet. 2022;1(1):15-22. doi: 10.31083/j.jgo.2022.01.003
  31. Carneiro MM, Pereira RM, Costa LM, Le-mos TA, Reis FM. Genetic mutations and endometrial hyperplasia: unlocking the secret. Int J Gynecol Cancer. 2019;29(6):1106-1113. doi: 10.1136/ijgc-2019-000474
  32. Dong Y, Lu J, Zhang Y, Zhang H, Wang L. Genetic mutations and endometrial hyperplasia: a review of the current advances. J Ovarian Res. 2020;13(1):31. doi: 10.1186/s13048-020-00629-4
  33. Guo F, Wang H. Molecular mechanism and targeted therapy of endometrial hyperplasia. J Oncol. 2020;2020:7282609. doi: 10.1155/2020/7282609
  34. Fu M, Feng Y, Fang H, Zhang J, Wang X. Relationship between progesterone resistance and endometrial abnormalities. J Med Res Pract. 2018;3(2):31-36. doi: 10.1016/j.jmrp.2017.08.003
  35. Kim J, Cho K, Lee Y, Kim J, Kim Y. En-dometrial hyperplasia: molecular pathogenesis and new therapeutic opportunities. Korean J Med Sci. 2020;35(4):e37. doi: 10.3346/jkms.2020.35.e37
  36. Sakai K, Yoshida T. Mechanisms of progesterone resistance in endometrial hyperplasia and their impact on pathogenesis and treatment. Biomed Pharmacother. 2020;1(3):44-53. doi: 10.1016/j.biopha.2019.109204
  37. Xu L, Hu C, Qiu C, Yang Z, Xu Q. Proge-sterone resistance and endometrial hyperplasia: latest research and treatment prospects. J Med Sci. 2021;41(2):41-47. doi: 10.3779/j.issn.1009-6574.2021.02.01
  38. Zhang Y, Guo H, Cui X, Song X, Wang Y. Molecular mechanisms of progesterone resistance and their clinical significance in endometrial hyperplasia. J Gynecol Obstet. 2022;1(1):15-22. doi: 10.31083/j.jgo.2022.01.003
  39. Carneiro MM, Pereira RM, Costa LM, Le-mos TA, Reis FM. Genetic mutations and endometrial hyperplasia: unlocking the secret. Int J Gynecol Cancer. 2019;29(6):1106-1113. doi: 10.1136/ijgc-2019-000474
  40. Dong Y, Lu J, Zhang Y, Zhang H, Wang L. Genetic mutations and endometrial hyperplasia: a review of the current advances. J Ovarian Res.

Downloads

Published

2025-04-18

How to Cite

Khaskhachikh , D., Potapov , V., & Poslavska , O. (2025). Factors of resistance to progestin therapy in endometrial hyperplasia in women. Морфологія / Morphologia / Morfologìâ, 17(1), 56–62. Retrieved from https://morphology.dma.edu.ua/article/view/278702

Issue

Vol. 17 No. 1 (2023)

Section

Статті

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.